Cladribine exerts an immunomodulatory effect on human and murine dendritic cells

International Immunopharmacology

Volumn 18, Issue 2, 2014, Pages 347-357

  Kraus, Stefan H P ^a   Luessi, Felix ^a   Trinschek, Bettina ^a   Lerch, Steffen ^a   Hubo, Mario ^a   Poisa Beiro, Laura ^a   Paterka, Magdalena ^a   Jonuleit, Helmut ^a   Zipp, Frauke ^a   Jolivel, Valérie ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cladribine; Dendritic cell; Immunomodulation

Indexed keywords

CD86 ANTIGEN; CLADRIBINE; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LEUKEMIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIGEN PRESENTING CELLS; APC; CARBOXYFLUORESCEIN SUCCINIMIDYL ESTER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CFSE; CLADRIBINE; CNS; CSF; DC; DENDRITIC CELL; DENDRITIC CELLS; EAE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOMODULATION; MAB; MIXED LEUKOCYTE REACTION; MLR; MONOCLONAL ANTIBODY; MS; MULTIPLE SCLEROSIS; PBMC; PERIPHERAL BLOOD MONONUCLEAR CELLS; PI; PROPIDIUM IODIDE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMOTAXIS; CLADRIBINE; CYTOKINES; DENDRITIC CELLS; DEXTRANS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; T-LYMPHOCYTES;

EID: 84892152406     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.11.027     Document Type: Article

References (68)

1. E. Beutler Cladribine (2-chlorodeoxyadenosine) Lancet 340 1992 952 956
2. K.L. McClain Drug therapy for the treatment of Langerhans cell histiocytosis Expert Opin Pharmacother 6 2005 2435 2441 (Pubitemid 41701046)
3. S. Weitzman, A.S. Wayne, R. Arceci, J.M. Lipton, and J.A. Whitlock Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature Med Pediatr Oncol 33 1999 476 481 (Pubitemid 29519713)
4. J.C. Davis Jr., H. Austin 3rd, D. Boumpas, T.A. Fleisher, C. Yarboro, and A. Larson et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis Arthritis Rheum 41 1998 335 343 (Pubitemid 28087702)
5. M. Schirmer, E. Mur, K.P. Pfeiffer, J. Thaler, and G. Konwalinka The safety profile of low-dose cladribine in refractory rheumatoid arthritis. a pilot trial Scand J Rheumatol 26 1997 376 379 (Pubitemid 27471223)
6. G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann, and P. Soelberg Sorensen et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 2010 416 426
7. G. Giovannoni, S. Cook, K. Rammohan, P. Rieckmann, P.S. Sorensen, and P. Vermersch et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis Lancet Neurol 10 2011 329 337
8. J.A. Koziol, A. Lucero, J.C. Sipe, J.S. Romine, and E. Beutler Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial Can J Neurol Sci 26 1999 283 289 (Pubitemid 29522813)
9. J.C. Sipe Cladribine for multiple sclerosis: review and current status Expert Rev Neurother 5 2005 721 727 (Pubitemid 41679640)
10. S. Seto, C.J. Carrera, M. Kubota, D.B. Wasson, and D.A. Carson Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes J Clin Invest 75 1985 377 383 (Pubitemid 15143475)
11. E. Van den Neste, S. Cardoen, F. Offner, and F. Bontemps Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review) Int J Oncol 27 2005 1113 1124
12. A. Klopfer, A. Hasenjager, C. Belka, K. Schulze-Osthoff, B. Dorken, and P.T. Daniel Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway Oncogene 23 2004 9408 9418 (Pubitemid 40069673)
13. R. Castejon, J.A. Vargas, M. Briz, E. Berrocal, Y. Romero, and J.C. Gea-Banacloche et al. Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia Leukemia 11 1997 1253 1257 (Pubitemid 27387301)
14. D. Barbieri, M.P. Abbracchio, S. Salvioli, D. Monti, A. Cossarizza, and S. Ceruti et al. Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells Neurochem Int 32 1998 493 504 (Pubitemid 28287203)
15. V. Singh, K.P. Chittappen, V. Gudi, K. Benardais, E.V. Voss, and M. Stangel 2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells Clin Exp Immunol 173 2013 288 297
16. K. Janiec, A. Wajgt, and Z. Kondera-Anasz Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis Med Sci Monit 7 2001 93 98 (Pubitemid 32125194)
17. H. Bartosik-Psujek, E. Belniak, K. Mitosek-Szewczyk, B. Dobosz, and Z. Stelmasiak Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine Acta Neurol Scand 109 2004 390 392 (Pubitemid 38698175)
18. V. Singh, E.V. Voss, K. Benardais, and M. Stangel Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia J Neuroimmune Pharmacol 7 2012 939 950
19. B. Laugel, F. Borlat, L. Galibert, A. Vicari, R. Weissert, and Y. Chvatchko et al. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity J Neuroimmunol 240-241 2011 52 57
20. A. Niezgoda, J. Losy, and P.D. Mehta Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis Folia Morphol 60 2001 225 228 (Pubitemid 32821634)
21. V. Siffrin, H. Radbruch, R. Glumm, R. Niesner, M. Paterka, and J. Herz et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis Immunity 33 2010 424 436
22. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408 (Pubitemid 34164012)
23. T. Kopadze, M. Dobert, V.I. Leussink, T. Dehmel, and B.C. Kieseier Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis Eur J Neurol 16 2009 409 412
24. K. Mitosek-Szewczyk, J. Tabarkiewicz, B. Wilczynska, K. Lobejko, J. Berbecki, and M. Nastaj et al. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis J Neurol Sci 332 2013 35 40
25. V. Singh, C.K. Prajeeth, V. Gudi, K. Benardais, E.V. Voss, and M. Stangel 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells Clin Exp Immunol 173 2013 288 297
26. S. Anguille, Y. Willemen, E. Lion, E.L. Smits, and Z.N. Berneman Dendritic cell vaccination in acute myeloid leukemia Cytotherapy 14 2012 647 656
27. R.M. Steinman, and J. Banchereau Taking dendritic cells into medicine Nature 449 2007 419 426 (Pubitemid 47509552)
28. K. Lotfi, G. Juliusson, and F. Albertioni Pharmacological basis for cladribine resistance Leuk Lymphoma 44 2003 1705 1712 (Pubitemid 37221044)
29. F. Bontemps, C. Meier, A. Delacauw, J. Balzarini, C. Galmarini, and E. van den Neste Study of the efficacy of a pronucleotide of 2-chloro-2′- deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells Nucleosides Nucleotides Nucleic Acids 25 2006 997 1000 (Pubitemid 44651836)
30. W.N. Wu, L.A. McKown, M.D. Moyer, and W. Cheung Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin) in animals and humans Xenobiotica 34 2004 591 606 (Pubitemid 38981372)
31. A. Gorski, P. Grieb, J. Makula, B. Stepien-Sopniewska, T. Mrowiec, and M. Nowaczyk 2-Chloro-2-deoxyadenosine - a novel immunosuppressive agent Transplantation 56 1993 1253 1257 (Pubitemid 23348712)
32. K. Jensen, L.A. Johnson, P.A. Jacobson, S. Kachler, M.N. Kirstein, and J. Lamba et al. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors Naunyn Schmiedebergs Arch Pharmacol 385 2012 519 525
33. S.V. Novitskiy, S. Ryzhov, R. Zaynagetdinov, A.E. Goldstein, Y. Huang, and O.Y. Tikhomirov et al. Adenosine receptors in regulation of dendritic cell differentiation and function Blood 112 2008 1822 1831
34. J. Liliemark, and C. Peterson Purine analogs and antifolates J.H.M. Schellers, H.L. McLeod, D.R. Newell, Cancer Clinical Pharmacology 2005 Oxford University Press Oxford 63 83
35. K. Girardi, A. Paviglianiti, M. Cirillo, A. Bianchi, G. Gherardi, and O. Annibali et al. Tuberculous meningoencephalitis in a patient with hairy cell leukemia in complete remission Clin Exp Hematop 52 2012 31 34
36. F. Bagnato, and I. Pirko Novel agents and emerging treatment strategies in multiple sclerosis. What role for cladribine? Clin Med Insights: Therapeutics 3 2011 425 439
37. J. Liliemark, and G. Juliusson On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans Cancer Res 51 1991 5570 5572
38. J.N. Stoop, R.A. Harry, A. von Delwig, J.D. Isaacs, J.H. Robinson, and C.M. Hilkens Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses Arthritis Rheum 62 2010 3656 3665
39. T.L. Papenfuss, N.D. Powell, M.A. McClain, A. Bedarf, A. Singh, and I.E. Gienapp et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity J Immunol 186 2011 3346 3355
40. S.R. McColl Chemokines and dendritic cells: a crucial alliance Immunol Cell Biol 80 2002 489 496
41. J.J. Oppenheim, C.O. Zachariae, N. Mukaida, and K. Matsushima Properties of the novel proinflammatory supergene "intercrine" cytokine family Annu Rev Immunol 9 1991 617 648
42. M. Sivina, E. Hartmann, T.J. Kipps, L. Rassenti, D. Krupnik, and S. Lerner et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia Blood 117 2011 1662 1669
43. H. Hamed, and S. Zaki Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy Egypt J Immunol 14 2007 63 72
44. C.S.S. Meagher, S. Hussain, M. Cameron, G. Arreaza, and T. Delovitch Cytokines and chemokines in the pathogenesis of murine type 1 diabetes P S Cytokines and Chemokines in Autoimmune Disease 2001 RG Landes Co Austin
45. R. Miyagishi, S. Kikuchi, T. Fukazawa, and K. Tashiro Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases J Neurol Sci 129 1995 223 227
46. T.L. Sorensen, M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, and V.A. Folcik et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients J Clin Invest 103 1999 807 815 (Pubitemid 29152626)
47. J.E. Simpson, J. Newcombe, M.L. Cuzner, and M.N. Woodroofe Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions J Neuroimmunol 84 1998 238 249 (Pubitemid 28248412)
48. C. McManus, J.W. Berman, F.M. Brett, H. Staunton, M. Farrell, and C.F. Brosnan MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study J Neuroimmunol 86 1998 20 29 (Pubitemid 28293946)
49. C. Prodinger, J. Bunse, M. Kruger, F. Schiefenhovel, C. Brandt, and J.D. Laman et al. CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system Acta Neuropathol 121 2011 445 458
50. W.J. Karpus, N.W. Lukacs, B.L. McRae, R.M. Strieter, S.L. Kunkel, and S.D. Miller An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis J Immunol 155 1995 5003 5010
51. M. Manczak, S. Jiang, B. Orzechowska, and G. Adamus Crucial role of CCL3/MIP-1alpha in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats J Autoimmun 18 2002 259 270 (Pubitemid 34970050)
52. D. Centonze, L. Muzio, S. Rossi, F. Cavasinni, V. De Chiara, and A. Bergami et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis J Neurosci 29 2009 3442 3452
53. S. Rossi, V. De Chiara, R. Furlan, A. Musella, F. Cavasinni, and L. Muzio et al. Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis Brain Behav Immun 24 2010 1379 1385
54. K. Hebel, M. Rudolph, B. Kosak, H.D. Chang, J. Butzmann, and M.C. Brunner-Weinzierl IL-1beta and TGF-beta act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4 + T cells J Immunol 187 2011 5627 5635
55. Y. Chung, S.H. Chang, G.J. Martinez, X.O. Yang, R. Nurieva, and H.S. Kang et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling Immunity 30 2009 576 587
56. M. Skarica, T. Wang, E. McCadden, D. Kardian, P.A. Calabresi, and D. Small et al. Signal transduction inhibition of APCs diminishes Th17 and Th1 responses in experimental autoimmune encephalomyelitis J Immunol 182 2009 4192 4199
57. J.M. Motta, C.R. Nascimento, and V.M. Rumjanek Leukemic cell products down-regulate human dendritic cell differentiation Cancer Immunol Immunother 59 2010 1645 1653
58. L. Yang, D.E. Anderson, C. Baecher-Allan, W.D. Hastings, E. Bettelli, and M. Oukka et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells Nature 454 2008 350 352
59. C.L. Fu, Y.H. Chuang, H.Y. Huang, and B.L. Chiang Induction of IL-10 producing CD4 + T cells with regulatory activities by stimulation with IL-10 gene-modified bone marrow derived dendritic cells Clin Exp Immunol 153 2008 258 268
60. K. Steinbrink, M. Wolfl, H. Jonuleit, J. Knop, and A.H. Enk Induction of tolerance by IL-10-treated dendritic cells J Immunol 159 1997 4772 4780 (Pubitemid 127471012)
61. H. Jonuleit, E. Schmitt, G. Schuler, J. Knop, and A.H. Enk Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells J Exp Med 192 2000 1213 1222
62. H. Muller, S. Hofer, N. Kaneider, H. Neuwirt, B. Mosheimer, and G. Mayer et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells Eur J Immunol 35 2005 533 545 (Pubitemid 40331330)
63. X. Zeng, T. Wang, C. Zhu, X. Xing, Y. Ye, and X. Lai et al. Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro PloS One 7 2012 e34830
64. K. Ghoreschi, J. Bruck, C. Kellerer, C. Deng, H. Peng, and O. Rothfuss et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells J Exp Med 208 2011 2291 2303
65. Q. Liu, X. Zhao, F. Frissora, Y. Ma, R. Santhanam, and D. Jarjoura et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma Blood 111 2008 275 284
66. C. Warnke, V.I. Leussink, N. Goebels, O. Aktas, A. Boyko, and B.C. Kieseier et al. Cladribine as a therapeutic option in multiple sclerosis Clin Immunol 142 2012 68 75
67. R. Hohlfeld Multiple sclerosis: cladribine - a contentious therapeutic contender for MS Nat Rev Neurol 7 2011 425 427
68. G. Comi, H.P. Hartung, N.C. Kurukulasuriya, S.J. Greenberg, and M. Scaramozza Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis Expert Opin Pharmacother 14 2013 123 136